Kasting Monica L, Wilson Shannon, Zollinger Terrell W, Dixon Brian E, Stupiansky Nathan W, Zimet Gregory D
Indiana University Richard M. Fairbanks School of Public Health, Department of Epidemiology, 1050 Wishard Blvd, RG5, Indianapolis, IN 46202, USA.
Indiana University School of Medicine, Department of Pediatrics, 410 W 10th Street Suite 1001, Indianapolis, IN 46202, USA.
Prev Med Rep. 2016 Dec 21;5:169-174. doi: 10.1016/j.pmedr.2016.12.013. eCollection 2017 Mar.
Among the identified barriers to HPV vaccination is the concern that women may compensate for their reduced susceptibility to cervical cancers by reducing cervical cancer screening. This exploratory study examined the relationship between cervical cancer screening rates and HPV vaccination. We conducted a cross-sectional survey using a convenience sample of women aged 21-35 attending a local minority health fair in July 2015. Data were analyzed in 2015-2016. Outcomes assessed were: receiving a Pap test within the last three years, awareness and comfort with current Pap test recommendations, and knowledge regarding the purpose of a Pap test. A total of 291 women were included in the analyses. Mean age was 28.5 years and 62% were non-Hispanic black. 84% had received a Pap test in the last three years and 33% had received at least one HPV vaccine. Logistic regression results showed that women who had been vaccinated did not have lower odds of having a Pap test in the past three years (OR = 1.32; 95% CI = 0.66-2.65). In an adjusted regression model controlling for age and race, vaccinated women were significantly more likely to have had a Pap test (AOR = 3.06; 95% CI = 1.37-6.83). Yet only 26% of women knew the purpose of a Pap test and the proportion who answered correctly was higher among non-Hispanic white women. Women who have been vaccinated for HPV are more likely to have been screened for cervical cancer. These results suggest areas for more robust studies examining pro-health attitudes, behaviors, and communication regarding vaccination and preventive screening.
在已确定的人乳头瘤病毒(HPV)疫苗接种障碍中,有一种担忧是女性可能会通过减少宫颈癌筛查来弥补其对宫颈癌易感性的降低。这项探索性研究考察了宫颈癌筛查率与HPV疫苗接种之间的关系。我们于2015年7月对参加当地少数族裔健康博览会的21至35岁女性进行了便利抽样,开展了一项横断面调查。数据于2015 - 2016年进行分析。评估的结果包括:在过去三年中接受巴氏试验、对当前巴氏试验建议的知晓度和接受度,以及关于巴氏试验目的的知识。共有291名女性纳入分析。平均年龄为28.5岁,62%为非西班牙裔黑人。84%的女性在过去三年中接受过巴氏试验,33%的女性至少接种过一剂HPV疫苗。逻辑回归结果显示,接种过疫苗的女性在过去三年中进行巴氏试验的几率并不低(比值比[OR]=1.32;95%置信区间[CI]=0.66 - 2.65)。在控制了年龄和种族的调整回归模型中,接种疫苗的女性进行巴氏试验的可能性显著更高(调整后比值比[AOR]=3.06;95% CI=1.37 - 6.83)。然而,只有26%的女性知道巴氏试验的目的,在非西班牙裔白人女性中回答正确的比例更高。接种过HPV疫苗的女性更有可能接受过宫颈癌筛查。这些结果表明需要开展更有力的研究,以考察关于疫苗接种和预防性筛查的促进健康的态度、行为及沟通。